The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements.

No definition available.

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number days of prior written notice to terminate the agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsNoticePeriod
Namespace Prefix:	elev_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty on net sales of licensed products under the collaboration and license agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts
Namespace Prefix:	elev_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of royalty payments payable under the collaboration and license agreements.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsRoyaltyPaymentsPayable
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_NIHAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ASSET PURCHASE AND LICENSE AGREEMENTS (Details) $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2019 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 USD ($)
Asset Acquisition [Line Items]
Research and development		$ 23,595		$ 15,476
Asset Purchase Agreement relating to Seribantumab
Asset Acquisition [Line Items]
Upfront payment	$ 3,500
Research and development		3,500
Milestone payments paid		0		$ 0
Asset Purchase Agreement relating to Seribantumab \| Maximum
Asset Acquisition [Line Items]
Milestone payments payable		$ 54,500
Dyax
Asset Acquisition [Line Items]
Number of days written prior notice to terminate agreement		90 days	90 days
Dyax \| Maximum
Asset Acquisition [Line Items]
Milestone payments payable		$ 9,300
Selexis
Asset Acquisition [Line Items]
Number of days written prior notice to terminate agreement		60 days	60 days
Royalty payments payable \| €			€ 200,000
Percentage of royalty on net sales of licensed products		1.00%	1.00%
Selexis \| Maximum
Asset Acquisition [Line Items]
Milestone payments payable, per licensed product \| €			€ 900
National Institute of Health \| Maximum
Asset Acquisition [Line Items]
Milestone payments payable		$ 400